Nurix Therapeutics (NRIX) Receivables - Other (2020 - 2026)

Nurix Therapeutics (NRIX) has 7 years of Receivables - Other data on file, last reported at $2.4 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $2.4 million, down 65.71% year-over-year; the trailing twelve-month figure through Feb 2026 was $2.4 million (down 65.71% YoY), and the FY2025 annual result was $5.0 million, changed 0.0% from the prior year.
• Receivables - Other fell to $2.4 million in Q1 2026 per NRIX's latest filing, from $5.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $7.0 million in Q1 2025 and troughed at $600000.0 in Q2 2024.
• A 5-year average of $2.8 million and a median of $2.0 million in 2024 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other soared 455.56% in 2023, then plunged 86.67% in 2024.
• A 5-year view of Receivables - Other shows it stood at $1.0 million in 2022, then soared by 300.0% to $4.0 million in 2023, then advanced by 25.0% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025, then slumped by 52.0% to $2.4 million in 2026.
• Business Quant data shows NRIX's Receivables - Other at $2.4 million in Q1 2026, $5.0 million in Q4 2025, and $1.7 million in Q3 2025.